

Eiji Shinozaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5960115/publications.pdf>

Version: 2024-02-01

105
papers

1,607
citations

361413

20
h-index

345221

36
g-index

114
all docs

114
docs citations

114
times ranked

2495
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 475-484.	1.3	3
2	KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1273-1283.	2.5	6
3	Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018. <i>Oncologist</i> , 2022, 27, e506-e517.	3.7	6
4	Real-world data analysis of antiangiogenic targeted treatments in second-line following anti-EGFR antibodies and FOLFOX in first-line for patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 43-43.	1.6	0
5	Clinical usefulness of postoperative serum carcinoembryonic antigen in colorectal cancer patients with liver metastases.. <i>Journal of Clinical Oncology</i> , 2022, 40, 178-178.	1.6	0
6	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. <i>JCO Precision Oncology</i> , 2022, 6, e2100383.	3.0	8
7	Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with) Tj ETQq1 1 0.784314 rgBT /Over multicentre, randomised phase II trial (NOMINATE trial). <i>BMJ Open</i> , 2022, 12, e055140.	1.9	6
8	Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer. <i>Advances in Therapy</i> , 2022, , 1.	2.9	3
9	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100535.	3.0	29
10	Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2022, 37, 1439-1447.	2.2	3
11	Clinical impact of DNA methylation status on first-line antiepidermal growth factor receptor treatment in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3528-3528.	1.6	0
12	Plasma <i>RAS</i> dynamics and anti-EGFR rechallenge efficacy in patients with <i>RAS/BRAF</i> wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3518-3518.	1.6	11
13	Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research. <i>International Journal of Clinical Oncology</i> , 2021, 26, 335-344.	2.2	6
14	Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 767-777.	2.3	8
15	Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. <i>PLoS ONE</i> , 2021, 16, e0246160.	2.5	7
16	Outcomes of Surgical Treatment for Patients with Anorectal Malignant Melanoma; Results of Nine Cases in a Single Institution. <i>Journal of the Anus, Rectum and Colon</i> , 2021, 5, 192-196.	1.1	0
17	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 674.	2.6	19
18	Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer. <i>Anticancer Research</i> , 2021, 41, 3905-3915.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	7.0	27
20	Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab. <i>Oncology Letters</i> , 2021, 22, 783.	1.8	7
21	Immunotherapy in Colorectal Cancer: Current and Future Strategies. <i>Journal of the Anus, Rectum and Colon</i> , 2021, 5, 11-24.	1.1	59
22	Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. <i>Cancer Medicine</i> , 2021, 10, 615-625.	2.8	10
23	Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting. <i>Dose-Response</i> , 2021, 19, 155932582110476.	1.6	1
24	Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer. <i>Cancer Medicine</i> , 2021, 10, 8820-8828.	2.8	10
25	A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. <i>Investigational New Drugs</i> , 2020, 38, 111-119.	2.6	6
26	Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 265-272.	2.3	47
27	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). <i>Clinical Cancer Research</i> , 2020, 26, 5887-5894.	7.0	44
28	Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan. <i>Annals of Surgical Oncology</i> , 2020, 27, 3307-3315.	1.5	20
29	Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient. <i>Scientific Reports</i> , 2020, 10, 17455.	3.3	1
30	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. <i>Cancers</i> , 2020, 12, 3236.	3.7	23
31	Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting. <i>ESMO Open</i> , 2020, 5, e000595.	4.5	2
32	Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1566.	3.7	15
33	A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO) <i>TJ ETQq1 1 0.78. #314 rgBT /Overl</i>		
34	Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. <i>BMC Cancer</i> , 2020, 20, 358.	2.6	4
35	A unique <i>ex vivo</i> tumor model: 3D cocultured system with cancer and stromal cells including blood microvessels. <i>Journal of Clinical Oncology</i> , 2020, 38, 211-211.	1.6	1
36	Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study. <i>Cancer Management and Research</i> , 2019, Volume 11, 5757-5764.	1.9	4

#	ARTICLE	IF	CITATIONS
37	Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing. <i>Biomedical Reports</i> , 2019, 11, 171-180.	2.0	4
38	ASO Author Reflections: Combining Intensive Neoadjuvant Therapy with Minimally Invasive Surgery: A Promising Future Strategy for Rectal Cancer with High-Risk Features. <i>Annals of Surgical Oncology</i> , 2019, 26, 753-754.	1.5	0
39	Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. <i>World Journal of Surgical Oncology</i> , 2019, 17, 100.	1.9	15
40	Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 307-313.	2.3	9
41	Clinical utility of circulating tumor DNA for colorectal cancer. <i>Cancer Science</i> , 2019, 110, 1148-1155.	3.9	106
42	Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 2507-2513.	1.5	32
43	Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer. <i>International Journal of Cancer</i> , 2019, 145, 2488-2495.	5.1	17
44	Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults. <i>Cancer Science</i> , 2019, 110, 1352-1363.	3.9	38
45	Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000590.	4.5	1
46	Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 17358.	3.3	67
47	Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. <i>Cancer Medicine</i> , 2019, 8, 408-417.	2.8	63
48	Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 518-525.	5.3	44
49	bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS179-TPS179.	1.6	2
50	Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 1186-1195.	5.1	67
51	Reply to "Comment on "Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREFAC) study". <i>British Journal of Cancer</i> , 2018, 118, 1278-1279.	6.4	0
52	Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer. <i>Gastric Cancer</i> , 2018, 21, 267-275.	5.3	12
53	A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. <i>International Journal of Clinical Oncology</i> , 2018, 23, 92-97.	2.2	13
54	Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel. <i>Oncotarget</i> , 2018, 9, 15219-15227.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 5283-5290.	1.9	5
56	Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8301-8307.	2.0	10
57	Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab. <i>Case Reports in Oncology</i> , 2018, 11, 601-608.	0.7	4
58	Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials. <i>Clinical Colorectal Cancer</i> , 2018, 17, e719-e732.	2.3	10
59	Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. <i>Cancer Science</i> , 2018, 109, 2567-2575.	3.9	7
60	Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker. <i>BMC Cancer</i> , 2018, 18, 406.	2.6	29
61	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3530-3530.	1.6	10
62	A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage III Colon Cancer – ACTOR Study. <i>Anticancer Research</i> , 2018, 38, 1741-1747.	1.1	6
63	TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. <i>Lancet Oncology</i> , 2017, 18, 1172-1181.	10.7	111
64	Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis. <i>International Journal of Clinical Oncology</i> , 2017, 22, 1060-1068.	2.2	9
65	Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2017, 17, 38.	2.6	21
66	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. <i>British Journal of Cancer</i> , 2017, 117, 1450-1458.	6.4	52
67	Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo.. <i>Journal of Clinical Oncology</i> , 2017, 35, 529-529.	1.6	2
68	Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines.. <i>Journal of Clinical Oncology</i> , 2017, 35, 741-741.	1.6	4
69	Prognostic factors of trastuzumab-based chemotherapy in patients with advanced HER2 positive gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 41-41.	1.6	1
70	Analysis of predictive factors of ramucirumab plus paclitaxel for advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 185-185.	1.6	0
71	Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0176745.	2.5	3
72	Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2016, 7, 34811-34823.	1.8	43

#	ARTICLE	IF	CITATIONS
73	Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases. <i>Investigational New Drugs</i> , 2016, 34, 468-473.	2.6	1
74	<i>RAS</i> mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. <i>International Journal of Cancer</i> , 2016, 139, 803-811.	5.1	38
75	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. <i>Gastric Cancer</i> , 2016, 19, 183-191.	5.3	95
76	Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer. <i>Gastric Cancer</i> , 2016, 19, 625-630.	5.3	4
77	Onset of neutropenia as an indicator of treatment response in the randomized phase II of TAS-102 vs placebo in Japanese patients with metastatic colorectal cancer (Study J003-10040030).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3557-3557.	1.6	5
78	A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3632-TPS3632.	1.6	1
79	The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)â€™ GI-SCREEN 2013-01-CRC sub-study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3573-3573.	1.6	1
80	Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. <i>Molecular and Clinical Oncology</i> , 2015, 3, 1053-1057.	1.0	15
81	Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?. <i>BMC Cancer</i> , 2015, 15, 760.	2.6	4
82	Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). <i>OncoTargets and Therapy</i> , 2015, 8, 1111.	2.0	10
83	Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3099.	4.3	45
84	Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 529.	2.0	7
85	Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab. <i>OncoTargets and Therapy</i> , 2015, 8, 2005.	2.0	3
86	A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 1653.	4.3	7
87	Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients. <i>OncoTargets and Therapy</i> , 2015, 8, 3329.	2.0	17
88	Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 243.	2.0	1
89	An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE).. <i>Journal of Clinical Oncology</i> , 2015, 33, 3544-3544.	1.6	19
90	ACEIs/ARBs to improve survival in advanced gastric cancer patients receiving S-1 plus cisplatin.. <i>Journal of Clinical Oncology</i> , 2015, 33, 174-174.	1.6	0

#	ARTICLE	IF	CITATIONS
91	A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study).. Journal of Clinical Oncology, 2015, 33, 758-758.	1.6	0
92	Phenotypic differences among RAS mutational variations in colorectal cancer (CRC): Analysis of 1,001 patients in single institute.. Journal of Clinical Oncology, 2015, 33, 649-649.	1.6	0
93	Clinical features and outcome of advanced or metastatic gastric cancer in young adult,analysis of 97 cases.. Journal of Clinical Oncology, 2015, 33, e15022-e15022.	1.6	0
94	Outcome of marked tumor marker increase in patients with advanced gastric cancer during chemotherapy without progression.. Journal of Clinical Oncology, 2015, 33, e15034-e15034.	1.6	0
95	Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute.. Journal of Clinical Oncology, 2014, 32, 3597-3597.	1.6	4
96	The efficacy of oxaliplatin-based adjuvant chemotherapy for stage IV colorectal cancer after R0 resection.. Journal of Clinical Oncology, 2014, 32, 638-638.	1.6	0
97	Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CAin a single reaction by multiplex assay kit. BMC Cancer, 2013, 13, 405.	2.6	42
98	Survival analysis of linitis plastica advanced gastric cancer patients receiving S-1 plus cisplatin.. Journal of Clinical Oncology, 2013, 31, e15105-e15105.	1.6	0
99	Concordance of HER2 and its related molecules between primary and paired liver metastatic sites in gastric cancer.. Journal of Clinical Oncology, 2013, 31, 4108-4108.	1.6	2
100	Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 486-486.	1.6	3
101	Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 610-610.	1.6	2
102	What are the limiting factors related to discontinuance of chemotherapy after failure of first-line S-1 plus CDDP in Japanese patients with advanced gastric cancer?. Journal of Clinical Oncology, 2012, 30, 149-149.	1.6	0
103	A phase I/II study of biweekly XELIRI plus bevacizumab for patients with metastatic colorectal cancer as second-line chemotherapy (BIXER study): Reports of phase I part and interim analysis of phase II part.. Journal of Clinical Oncology, 2012, 30, 643-643.	1.6	0
104	Irinotecan Plus Cisplatin for Therapy of Small-cell Carcinoma of the Esophagus: Report of 12 Cases from Single Institution Experience. Japanese Journal of Clinical Oncology, 2008, 38, 426-431.	1.3	47
105	NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	1